1. Introduction {#sec0005}
===============

Middle East respiratory syndrome (MERS) is an emerging respiratory disease caused by the MERS coronavirus (MERS-CoV). MERS has been endemic mainly in Saudi Arabia since 2012 ([@bib0015]; [@bib0020]). As of 15 March 2018, there have been 2144 confirmed cases, with 750 deaths, reported from 27 countries \[The World Health Organization (WHO), Global Alert and Response (GAR), Coronavirus infections, updated on 15 March 2018, <http://www.who.int/csr/don/15-march-2018-mers-oman/en/>\].

According to the case definition of the WHO, at least two distinct genomic targets are required for a positive diagnosis \[WHO, GAR, Revised interim case definition for reporting to WHO -- Middle East respiratory syndrome coronavirus (MERS-CoV), updated on 3 July 2013, <http://www.who.int/csr/disease/coronavirus_infections/case_definition/en/index.html>\]. Therefore, many genetic diagnostic methods have been developed for the stable and reliable diagnosis of MERS-CoV infections. Currently, the main diagnostic method of MERS-CoV is real-time RT-PCR assays, and the primer/probe sets \[upE and open reading frame (ORF) 1a\] developed by Corman et al. are widely used as standard assays ([@bib0030], [@bib0035]).

The loop-mediated isothermal amplification (LAMP) method amplifies specific nucleotide sequences using a set of four or six unique primers ([@bib0095]; [@bib0105]). This method is relatively quick and user-friendly; amplification signals can be readily detected within an hour, and it only requires a single incubation temperature. As such, various LAMP assays have been developed for the detection of a wide range of pathogens, such as bacteria ([@bib0005]; [@bib0050]; [@bib0140]), parasites ([@bib0010]; [@bib0160]), and viruses ([@bib0055]; [@bib0060]; [@bib0085]; [@bib0120]; [@bib0145]) including MERS-CoV ([@bib0025]; [@bib0080]; [@bib0125]).

A reverse transcription (RT)-LAMP assay for the detection of MERS-CoV was developed by our group recently ([@bib0125]), which employs a primer set targeting the viral nucleocapsid (N) sequence, comparable to standard real-time RT-PCR assays. In the LAMP assay, positive signals are indicated by turbidity that results from magnesium pyrophosphate precipitation following LAMP reaction. However, in this mechanism, the possibility of unexpected signals derived from primer dimer and/or non-primer reactions cannot be excluded ([@bib0100]). There is also a possibility of detecting turbidity if the host-derived DNA makes LAMP product non-specifically. Thus, if unexpected signals are detected, it is very difficult to identify the origin of the signal. The validity of MERS-CoV detection by previous RT-LAMP assay has been confirmed ([@bib0125]), but the mechanism of turbidity detection can be improved.

Florescence dye (calcein, etc.) or DNA intercalator can be added for fluorescence monitoring (<http://loopamp.eiken.co.jp/e/tech/detect_index.html>), which may help to improve turbidity detection. The addition of DNA intercalator was used in Zika virus detection ([@bib0075]). However, the detection principle of these methods is the same as turbidity detection. Using fluorescence labeled primer can solve the problem of non-primer-derived signals. Recently, [@bib0045] reported RT-LAMP assays for detection of vesicular stomatitis, foot and mouth diseases, and swine vesicular disease viruses using fluorescence labeled forward inner primers (FIPs) or backward inner primers (BIPs). However, this study used 5´ end-labeled primers. Therefore, if the fluorescent primer causes non-specific extension at the 3′ end, unexpected signals will be detected. To avoid non-specific signals, melting curve analysis of the LAMP amplicon is useful to confirm amplification of the targeted sequence ([@bib0045]; [@bib0075]). However, melting curve analysis requires incubation of at a higher temperature than that LAMP, and requires additional time after amplification, which negates the main advantage of LAMP.

In this study, to address these problems, a quenching probe 3G (QProbe) was used for monitoring RT-LAMP. In QProbe, the fluorescence dye is labeled at the 3´ end of the primer. Therefore, the extension of the primer sequence is blocked by dye even if the primer anneals non-specifically at its 3´ end. Use of QProbe can detect primer-derived signals only, and thus can avoid detecting non-specific amplification caused by fluorescent primer. In addition, to validate a positive MERS-CoV diagnosis, an additional primer set (targeting the ORF1a region) for use in QProbe RT-LAMP assays was developed to enable to confirm MERS cases only by QProbe RT-LAMP.

2. Materials and methods {#sec0010}
========================

2.1. Viruses {#sec0015}
------------

MERS-CoV EMC strain was kindly provided by Ron A. M. Fouchier, Erasmus Medical Center, Rotterdam, the Netherlands. MERS-CoV was propagated and titrated using Vero cells. Human respiratory syncytial viruses (RSV; Long, A2, B WV/14617/85 and 18537) were obtained from the American Type Culture Collection (ATCC). Human metapneumovirus (HMPV; Sendai-H/2404/2003) was obtained from the Virus Research Center, Sendai Medical Center, Japan. Human coronavirus (HCoV)-229E isolates ATCC VR-740 and Sendai-H/1121/04 ([@bib0115]) were used. HCoV-NL63 was supplied by Dr. Lia van der Hoek, University of Amsterdam, the Netherlands. HCoV-OC43 isolate ATCC VR-1558 was used. SARS coronavirus (Frankfurt strain) was supplied by Dr. J. Ziebuhr, University of Würzburg, Germany. Human parainfluenza viruses (PIV) 1 (strain C35) and 3 (strain C243) were obtained from ATCC. Adenoviruses (ADVs) (serotype 3, strain G.B.; serotype 4, strain RI-67; and serotype 7, strain Gomen) were obtained from ATCC. Viruses were propagated and titrated using HEp-2, HeLa, RD, Vero cells, or LLC-Mk2 cells ([@bib0130]). Influenza viruses \[Flu; A/California/7/2009 (H1N1pdm), A/Victoria/210/2009 (H3N2), and B/Brisbane/60/2008\] were propagated and titrated using MDCK cells. Clinical isolates of HCoV-OC43 (Tokyo/SGH-36/2014, LC315646: Tokyo/SGH-61/2014, LC315647: Tokyo/SGH-06/2015, LC315648) and HKU1 (Tokyo/SGH-15/2014, LC315050: Tokyo/SGH-18/2016, LC315051) were isolated and propagated using human bronchial tracheal epithelial cells (Lifeline Cell Technology, Frederick, MD, USA) that were cultured and differentiated at the air--liquid interface.

2.2. Construction of primers for QProbe RT-LAMP {#sec0020}
-----------------------------------------------

For amplification of the N sequences, the primer set reported previously was utilized ([@bib0125]). The primer set for the amplification of the ORF1a region was constructed using the online LAMP primer design software (PrimerExplorer V4; <http://primerexplorer.jp/e/>) based on the sequence of the MERS-CoV EMC strain (GenBank [JX869059.2](http://JX869059.2){#intr0025}). The nucleotide sequence and concentration of primers used in each reaction are listed in [Table 1](#tbl0005){ref-type="table"} . For the detection of the RT-LAMP reaction by fluorescent signals, the QProbe was used (Nippon Steel & Sumikin Eco-Tech Corp., Tsukuba, Japan) ([@bib0135]). For primer sets targeting N and ORF1a, QProbes were constructed based on LB primers, and several nucleotides were added to LB primers ([Table 1](#tbl0005){ref-type="table"}). The final reaction mixture contained 1 pmol of QProbe-LBs and the six general MERS-CoV primers.Table 1Primer sets for MERS-CoV QProbe RT-LAMP assay.Table 1**N**Primer sequence (5′--3′, EMC, JX869059.2)PositionVolume (pmol/test)Number of matched sequences on GenBankPercentage of matched sequencesN-F3GCTCCCAGGTGGTACTTCT28848--288665293/30097.7N-B3cagtcccctcaatgtggaag29061--290425300/300100.0N-FIPtcatggacccaaacgatgccatACTGGAACTGGACCCGAAG28939--2891840299/30099.7+28872--28890245/30081.7N-BIPGCTCCTTCAACTTTTGGGACGCtagtaccgggcgcgaatt28956--2897740291/30097.0+29028--29011293/30097.7N-LFcggaatgggagtgctg28906--2889120300/300100.0N-LBGGAACCCTAACAATGATTCAGCT28978--2900010285/30095.0N-LB-QPGGAACCCTAACAATGATTCAGCTATTGTTACAC28978--290101**ORF1a**Primer sequence (5′--3′, EMC, JX869059.2)PositionVolume (pmol/test)Number of matched sequences on GenBankPercentage of matched sequencesORF1a-F3GCCTACTTTGGATGTGAGG1572--15905278/278100.0ORF1a-B3acaacgaactctcccaca1753--17365279/279100.0ORF1a-FIPtaaagatggagtctccaatccttgaAAGGTACTATGTACTTTGTGCC1656--163240264/27895.0+1591--1612239/27886.0ORF1a-BIPGTACTGGCTCTTGGAACAAGGagttaagggaatgctgagt1663--168340278/278100.0+1734--1716278/27999.6ORF1a-LFacaacagacttagctctag1612--163020278/278100.0ORF1a-LBGGTCACTCAAATTGCTAACATG1682--170320253/27990.7ORF1a-LB-QPGGTCACTCAAATTGCTAACATGTTCTTGGAACAGAC1682--17171[^1][^2]

2.3. Extraction of nucleic acids from virus stocks {#sec0025}
--------------------------------------------------

RNA was extracted from viral stocks using TRIzol LS, TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA), QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) or MagnaPure Compact Nucleic Acid Isolation kit (Roche, Basel, Switzerland), according to the manufacturer's instructions. Viral DNA was extracted using the SimplePrep Reagent for DNA (Takara-Bio Inc., Shiga, Japan), according to the manufacturer's instructions. Total RNA and genomic DNA were quantified using standard methods of measuring the OD value. For sensitivity assays, to isolate RNA from virion only, Vero cells were infected with MERS-CoV, and incubated for 4 days. Cell supernatants were then collected and centrifuged at 1500×*g* for 30 min at 4 °C, and the supernatants were treated with RNaseA (Nippongene, Tokyo Japan) at a concentration of 10 μg/mL for 30 min at 37 °C to exclude non-viral RNA as previously reported ([@bib0125]). The MERS-CoV RNA copy number was calculated based upon the standard curve generated by real-time RT-PCR assay using the upE primer set ([@bib0030]) and a positive control RNA template. Total RNAs were diluted in ribonuclease-free water containing 10 μg/mL of ribonucleic acid from baker's yeast (R6750; Sigma-Aldrich, St. Louis, MO, USA) as carrier RNA.

2.4. RT-LAMP assay {#sec0030}
------------------

The QProbe RT-LAMP assay was performed in a 25-μl (total) reaction mixture containing the appropriate amount of primer sets (see [Table 1](#tbl0005){ref-type="table"}), 1.4 mM of each deoxynucleoside triphosphates, 0.5% Tween 20, 8 mM MgSO4, 30 mM KCl, 20 mM Tricine (pH 8.6), 16 U of *Bst* DNA polymerase (New England Biolabs, Ipswich, MA, USA), 1 U of avian myeloblastosis virus reverse transcriptase (Thermo Fisher Scientific), and the extracted RNA. As a negative control, PCR-graded water containing carrier RNA only was utilized. The reaction mixture was incubated at 63 °C for 30 min in a thermostatic fluorometer capable of detecting FAM dye, which included LightCycler 480 (Roche), ABI 7500 Fast (Thermo Fisher Scientific), or ESEQuant TS2 tube scanner (Qiagen).

As the positive control for amplification of the viral N region, a previously synthesized RNA was utilized ([@bib0125]). To synthesize the control RNA for amplification of ORF1a region, the EMC strain sequence (1000--2000) was subcloned into pGEM-T Easy vector and subsequently amplified using PrimeSTAR MAX (Takara-Bio Inc.) and the following primers: 5′-TAATACGACTCACTATAGGGTCATCACATTAAAGAACAATCTATA-3′, and 5′-GGTTGCAACTTTCTTAAAGGACTCAC-3′. The amplicons were gel-purified and used as templates for RNA transcription using the MEGAscript T7 Transcription Kit (Thermo Fisher Scientific). The resultant RNA transcripts were quantified based on the OD value, and the copy number was calculated. The RNA was diluted in ribonuclease-free water containing 10 μg/mL of yeast RNA.

To evaluate the sensitivities of each primer set for detection of various target sequences, point mutations were introduced into the N and ORF1a sequences on plasmid by site-direct mutagenesis. The control RNA transcripts with the incorporated mutations were generated as described above.

2.5. Real-time RT-PCR {#sec0035}
---------------------

Real-time RT-PCR assays using upE and ORF1a primer sets ([@bib0030], [@bib0035]) were performed using a QuantiTect Probe RT-PCR kit (Qiagen) and a LightCycler 480 or LightCycler96 Instrument (Roche) as per the manufacturers\' instruction. The amplification conditions as previously reported were utilized ([@bib0030], [@bib0035]).

2.6. Processing of clinical specimens {#sec0040}
-------------------------------------

All experiments using human clinical specimens were approved by the Research and Ethical Committee for the Use of Human Subjects of the National Institute of Infectious Diseases, Japan (Approval \#746) ; the Ethical Committee of Showa General Hospital (Approval \#REC-094); and the Research Ethics Committee, Faculty of Medicine, King Abdulaziz University, Kingdom of Saudi Arabia (Approval \#121-16). Clinical specimens diagnosed to be positive for other respiratory pathogens were used for the evaluation of non-specific reaction in MERS-CoV-negative specimens. From January 2014 to February 2016, 19 nasal aspirates, secretions, or swabs were collected from patients presenting with influenza-like illnesses at the outpatient pediatrics clinic of Showa General Hospital. Parents or legal guardians of all children/minor participants provided written informed consent. Specimens were collected in 1 ml of universal transport medium (Copan Italia, Brescia, Italy), and RNA extraction was performed as described above. Detection of other respiratory pathogens was confirmed by real time RT-PCR as previously described ([@bib0040]; [@bib0065]). The presence of MERS-CoV was determined by QProbe RT-LAMP, using the protocol described above.

The QProbe RT-LAMP assay using MERS-CoV positive specimens was performed in the Special Infectious Agents Unit, King Abdulaziz University, Jeddah, Saudi Arabia, using lyophilized reaction mixtures in 12 stripe tubes and an ESEQuant TS2 tube scanner (Qiagen). Specimens used for validation were archived specimens collected from MERS cases since 2014. These were stored at −80 °C until testing. Total RNA (5 μL) extracted from MERS-CoV-positive specimens that were pre-tested by real-time RT-PCR was mixed with 20 μL of RT-PCR-grade water (Thermo Fisher Scientific), and was subsequently added to each well in the tube strip, and then used for MERS-CoV detection. Quenching signals were detected using the ESEQuant TS2 tube scanner at 63 °C for 30 min.

3. Results {#sec0045}
==========

3.1. Sensitivity of the QProbe RT-LAMP assay {#sec0050}
--------------------------------------------

The detection principle of QProbe is shown as in the schematic diagram of [Fig.1](#fig0005){ref-type="fig"} ; fluorescence from the fluorophore bound to the cytosine residue at the 3′ end of the QProbe is quenched by the guanine residue present in the target sequence during hybridization ([Fig. 1](#fig0005){ref-type="fig"}a). The positive signal is shown as quenching of fluorescence, which generates a reverse sigmoid curve ([Fig. 1](#fig0005){ref-type="fig"}b). In contrast, negative signals due to the lack of fluorescence quenching generate a straight line ([Fig. 1](#fig0005){ref-type="fig"}b). The detection limit of the QProbe RT-LAMP assay was determined using serially diluted MERS-CoV RNA templates and was evaluated in comparison to those of real-time RT-PCR (upE and ORF1a) and RT-LAMP (turbidity) assays ([Table 2](#tbl0010){ref-type="table"} ). Although target regions of QProbe RT-LAMP assays were different from real-time RT-PCR assays, the validation was performed using copy number-determined viral RNA, and each amplification was performed using the same samples. As reported previously, both real-time RT-PCR and RT-LAMP assays are capable of detecting MERS-CoV RNA at a copy level as low as 20 ([@bib0030], [@bib0035]; [@bib0125]). As shown in [Table 2](#tbl0010){ref-type="table"}, QProbe RT-LAMP assays, which targeted N and ORF1a sequences, were able to detect MERS-CoV RNA at a similar level, comparable to real-time RT-PCR and RT-LAMP. These data indicate that the sensitivity of QProbe RT-LAMP assays is similar to that of existing genetic diagnostic methods.Fig. 1a) Schematic representation of quenching probe (QProbe). QProbe is labeled with fluorescent dye at the cytosine residue at the 3′ end. When the QProbe hybridizes with the target, fluorescence is quenched by the guanine residue present in the target sequence. b) Images of detecting fluorescence quenching. Fluorescence RT-LAMP (N and ORF1a) was performed with serially diluted MERS-CoV viral RNA using the LightCycler480 instrument. The wavelength used for signal detection is the same as FAM. Negative signal is represented by an upper line. Positive signal is represented by a reverse S-shaped curve. NC, negative control.Fig. 1Table 2Sensitivity of QProbe RT-LAMP assays.Table 2Copies/reaction20002002020.2Sensitivity (copies/reaction)Time required (h)Real-time RT-PCRPositive/Number　 upE6/66/65/61/60/66.32 ORF1a6/66/64/60/60/613.62  Copies/reaction20002002020.2RT-LAMPPositive/Number N (turbidity)6/66/62/61/60/6200.5 N (QP)8/88/83/81/80/8200.5 ORF1a (QP)8/88/85/80/80/8150.5[^3]

3.2. Specificity of the QProbe RT-LAMP assays {#sec0055}
---------------------------------------------

Next, the specificity of QProbe RT-LAMP was determined using various respiratory virus isolates ([Table 3](#tbl0015){ref-type="table"} ). For both N and ORF1a primer sets, no cross reaction was detected with other respiratory pathogens included in this study. Similarly, no cross-reactivity was observed in the QProbe RT-LAMP assay where clinical specimens positive for other respiratory pathogens (determined by real-time RT-PCR) were utilized ([Table 4](#tbl0020){ref-type="table"} ). These data demonstrate that QProbe RT-LAMP possessed a high specificity for the diagnosis of MERS-CoV.Table 3Specificity of QProbe RT-LAMP assays.Table 3Primer setStrainName of isolateAmountNORF1aMERS-CoVEMC1 × 10^5^　copies++HCoV-229EATCC VR-7402.5 × 10^4^　PFU----Sendai-H/1121/045 × 10^3^　PFU----Niigata/01/084 × 10^2^　PFU----HCoV-NL631 × 10^2^　FFU----HCoV-HKU1Tokyo/SGH-15/20145 × 10^4^　copies----Tokyo/SGH-18/20166 × 10^2^　copies----HCoV-OC43ATCC VR-15582.5 × 10^2^ TCID50----Tokyo/SGH-36/20142 × 10^5^　copies----Tokyo/SGH-61/20141 × 10^6^　copies----Tokyo/SGH-06/20161 × 10^5^　copies----SARS-CoVFrankfurt2 × 10^6^　TCID50----  Other respiratory pathogensADV 3G.B.2 × 10^6^　TCID50----ADV 4RI-672 × 10^6^　TCID50----ADV 7Gomen2 × 10^6^　TCID50----  PIV1C-351.2 × 10^3^ PFU----PIV3C-2431 × 10^5^　PFU----  RSV ALong5 × 10^7^　copies----RSV AA25 × 10^5^　copies----RSV BCH/185375 × 10^7^　copies----RSV BB15 × 10^6^　copies----HMPVSendai-H/2404/20031.2 × 10^6^ PFU----  InfluenzaA(H1N1)pdm09A/California/7/20094 × 10^3^　TCID50----A(H3N2)A/Victoria/210/20091.25 × 10^6^　TCID50----BB/Brisbane/60/20081.25 × 10^4^　TCID50----[^4][^5][^6]Table 4QProbe RT-LAMP assays using clinical specimens positive for other respiratory viruses.Table 4SpecimenTypeDetected virusesPrimer setNumberNameCqNameCqNameCqNORF1aF14-15Nasal secretionHCoV-HKU123.7----F14-61Nasal aspirationHCoV-OC4318.3ADV233.1Rhino31.6----F16-18Nasal secretionHCoV-HKU125.1----F16-65Nasal aspirationHCoV-OC4324.0RSV A34.3----F14-56Nasal aspirationRSV A22.0ADV424.8----F15-25Nasal aspirationHBoV25.5Rhino26.9----F15-35Nasal aspirationPIV328.9----F15-42Nasal aspirationRSV B21.0HBoV31.9----F15-47Nasal aspirationADV228.3Rhino19.7----F15-50Nasal aspirationPIV432.0----F15-52Nasal aspirationRSV B19.5----F16-55Nasal secretionHMPV25.0----F15-56Nasal aspirationRSV A27.2ADV222.5----F15-7Nasal secretionFluA, H319.1----F16-9Nasal swabFluA, H1pdm22.2----F16-17Nasal secretionFluA, H318.6----F16-26Nasal secretionFluA, H1pdm20.6----F16-44Nasal secretionFluB21.0----F16-56Nasal secretionFluB18.6----  Positive control (viral RNA)++Negative control----[^7]

To evaluate the accuracy of QProbe RT-LAMP in detecting MERS-CoV from human specimens, QProbe RT-LAMP assays were performed using seven total RNAs extracted from clinical specimens that were initially confirmed to be MERS-CoV-positive by real-time RT-PCR (upE) ([Table 5](#tbl0025){ref-type="table"} ). Two MERS-CoV negative specimens were used as negative controls. Taking into consideration the recent MERS case occurrence rate, it was difficult to obtain fresh specimens; therefore, stored specimens were used for validation. Specimens deemed to be positive had quantification cycle values of 20.2--30.9 for the upE set. Using the N and ORF1a primer sets, QProbe RT-LAMP confirmed a positive diagnosis for all seven positive samples and a negative diagnosis for the other two. In short, the QProbe RT-LAMP assays developed in this study were capable of detecting MERS-CoV from human clinical specimens.Table 5QProbe RT-LAMP assays using clinical specimens positive for MERS-CoV viruses.Table 5SpecimenReal-time RT-PCRQProbe RT-LAMPNo.upECq valueNORF1a1+20.2++2+26.3++3+23.4++4+30.6++5+30.9++6+22.7++7+25.8++8--\>40----9--\>40----[^8]

3.3. Validations for mismatched sequences {#sec0060}
-----------------------------------------

The primer sets utilized in this study were constructed based on the conserved region of the N protein and ORF1a from the MERS-CoV EMC strain. However, significant genetic variations are present in these viral genomic regions as demonstrated by the large amount of sequences registered in GenBank. As shown in [Table 1](#tbl0005){ref-type="table"}, 300 and 278/9 variations of nucleotide sequences for N and ORF1a have been registered in the database, with the majority of them showing a complete match to the corresponding primer set. Mismatches (1--3 base-pairs) were identified in several sequences when aligned with our primers (see Supplemental figure). In particular, the FIP primers had a high mismatch rate in the F2 region; the identities were 81.7% for N set and 86.0% for ORF1a set ([Table 1](#tbl0005){ref-type="table"}). To determine whether QProbe RT-LAMP could amplify target sequences with mismatches to our primers, a panel of N and ORF1a RNA templates were synthesized by *in vitro* transcription, and QProbe RT-LAMP assays were performed using the appropriate primer sets ([Table 6](#tbl0030){ref-type="table"} for N, [Table 7](#tbl0035){ref-type="table"} for ORF1a). The detection limit of QProbe RT-LAMP for the EMC isolate sequence was 7.3--15.8 copies. QProbe RT-LAMP assays showed similar levels of amplification among all RNA template sequences, compared with that of the EMC isolate. The MERS-CoV sequences with mismatches were either of camel and/or human origin. Regardless of the target sequence origin, QProbe RT-LAMP well tolerated the nucleotide mismatches (1--3 base-pairs) without affecting the overall assay performance. In the previous study, mismatch in the B2 region (G29018T) slightly altered the amplification efficiency of RT-LAMP, leading to a five-fold decrease in detection sensitivity ([@bib0125]). In contrast, the amplification efficiency in the QProbe RT-LAMP assays was not affected by mismatch in this region ([Table 6](#tbl0030){ref-type="table"}). These findings indicate that the QProbe RT-LAMP assays could be used for the detection of all MERS-CoV isolates reported thus far, including for camels and humans.Table 6Sensitivity of QProbe RT-LAMP using sequence with mismatches to the N primer set.Table 6Position[a](#tblfn0005){ref-type="table-fn"}Accession No.Sensitivity (copies)C28862TKM210278, KM210277, KM01534815.8C28862T, T28880CKJ7825507.3C28865T, T29000C**KX108943**7.3C28865T, T28880C**KT368867, KT368866**7.3C28873TKU851859, **KT368886, KT368885, KT368884, KT368883, KT368882, KT368881, KT368880, KT368871**3.4T28880CKU710265, KU710264, **KT877351, KT877350,** KT861628, KT806055, **KT368890, KT368887, KT368857, KT368856, KT368855, KT368854, KT368853, KT368852, KT368851, KT368850, KT368849, KT368845, KT368844, KT368843, KT368832, KT368831, KT368830, KT368829, KT368828, KT368827**, KP769415, KP223131, KM044034, KM044033, KM044032, KM027261, KM027260, KM027259, KM027258, KM027257, KM027256, KM027255, KJ829365, **KJ713296, KJ713295, KJ650098**15.8T28880C, A28889G**KT368875**3.4T28928G**KT368834**3.4T28958CKJ15690515.8G28976A**KT368865, KT368864, KT368863, KT368862, KT368861, KT368860, KT368859, KT368858**3.4C28982TKJ47710215.8C28996TKT121581, KT121580, KT121579, KT121578, KT121577, KT121576, KT121575, KT121574, KT121573, KT121572, KM027262, KJ813439, KF96122115.8G29018TKJ556336, KJ156944, KJ156883, KF958702, **KF917527**15.8G29018A**KT368826**3.4C29021T**KT368873**3.4JX869059 (QProbe)15.8JX869059 (turbidity)7.3[^9][^10]Table 7Sensitivity of QProbe RT-LAMP using sequences with mismatches to the ORF1a primer set.Table 7Position[a](#tblfn0010){ref-type="table-fn"}Accession No.Sensitivity (copies)C1604T**KX108942, KX108941, KX108940, KX108939, KX108938, KX108937, KU242424, KU242423, KT751244,** KT156561, KT156560**, KP719933, KP719932, KP719931, KP719930, KP719929, KP719928, KP719927,** KP209313, KP209312, KP209311, KP209310, KP209309, KP209308, KP209307, KP209306, KJ650297, KJ650296, KJ650295, KJ361503, KJ361502, KJ361501, KJ361500, KJ361499, KJ156896, KJ156863, KF7450687.3A1650GKX1546871.6A1650G, C1685T**KX108944, KT368875, KT368832. KT368831, KT368830, KT368829**, KR011266, KR011265, KR011264, KR011263, **KJ713299, KJ713297, KJ713296, KJ713295**3.4A1650G, C1685T, T1694C**KJ713298**7.3C1685TKT861628, **KT368824**, KM027257, KJ556336, KJ156949, KJ156944, KJ156938, KJ156881, KF958702, **KF917527**15.8C1696T**KT368826**15.8T1718C**KX108943**1.6JX869059 (QProbe)7.3[^11][^12]

4. Discussion {#sec0065}
=============

Real-time RT-PCR is the most commonly used technique for the detection and confirmation of MERS-CoV infection. According to the case definition outlined by the WHO, positive amplification of at least two different virus-specific genomic targets is required for case confirmation. Two real-time RT-PCR assays were developed by Corman et al., using primer sets targeting upE and ORF1a region. These assays have been proven to be highly sensitive and specific; therefore, they are used as the standard diagnostic method for MERS-CoV ([@bib0030], [@bib0035]). However, PCR amplification involves a relatively long running process and may be unsuitable for field-based studies. Recently, other genetic diagnostic methods using different mechanisms have been developed, which include RT-LAMP ([@bib0025]; [@bib0125]) and reverse transcription isothermal recombinase polymerase amplification (RT-RPA) ([@bib0150]). In this study, the QProbe RT-LAMP targeted different positions in the MERS-CoV genome \[ORF1a (nt 1572--1753) and N\] from Corman's assays \[ORF1a (nt 18265--18314) and upE\]. Two positives in the QProbe RT-LAMP or real-time PCR assays are enough, to confirm the presence of MERS-CoV. However, this means if the specimen is positive in two of four sets, it can be considered positive for MERS-CoV; if one of the real-time RT-PCR assay is negative, one positive QProbe RT-LAMP is sufficient for case confirmation, and vice versa. Thus, these techniques have improved the sensitivity and diagnostic outcomes of MERS-CoV by increasing the number of viral genomic targets available for amplification.

The results of RT-LAMP can be detected at the endpoint by checking magnesium pyrophosphate precipitation or fluorescent signal generated by DNA intercalators under ultraviolet light ([@bib0090]). Because they are easy to use, and they do not require large equipment for processing, RT-LAMP assays are more suitable for field-based studies. However, in turbidity monitoring, the salt accumulation accompanied by the LAMP reaction can be induced by primer dimers and/or non-primer reactions ([@bib0100]). It is possible to detect unexpected increase in turbidity derived from non-primer signal, such as fragments of host DNA. Therefore, in this study, we developed a fluorescent RT-LAMP method with the addition of QProbes, in which only fluorescence quenching-derived from the probes was measured as a positive signal ([@bib0070]). As such, QProbes provide additional specificity for detection as they bind to unique nucleotides that are only present in the target sequence and amplicon by LAMP primers. This means that a positive signal in the QProbe RT-LAMP assay is dependent on the primer reaction only. In addition, labeling the 3′ end with fluorescence dye abrogates non-specific signals derived from primers because extension of the QProbe is physically blocked by the dye. Thus, QProbe allows for highly specific detection under isothermal conditions and in a short time without melting curve analysis. Furthermore, materials used in QProbe RT-LAMP assays can be prepared as lyophilized form and packaged into diagnostic kits, increasing product integrity during shipment and handling. As demonstrated using clinical specimens ([Table 5](#tbl0025){ref-type="table"}), this assay could be run in a portable device (*e.g*., ESEQuant TS2) and be completed in 30 min or less for accurate diagnosis of MERS-CoV, making it more suitable for field-based studies. We also showed that the two primer sets constructed in the study (targeting the viral N and ORF1a sequences) were equally capable of detecting MERS-CoV RNA. This means that a positive diagnosis can be confirmed by QProbe RT-LAMP alone without the need for other confirmation methods.

To determine the homology between the QProbe RT-LAMP primers and the generic variants of N and ORF1a, nucleotide sequence alignment was performed using 300 N and 279 ORF1a sequences available on GenBank. Most primer sets described in this study matched 90--100% of sequence variants, except for the FIP primers, which had matched 81.7% and 86.0% of N and ORF1a sequences, respectively. Our data indicate that these mismatches did not affect the ability of QProbe RT-LAMP assays to amplify these target sequences. In fact, these assays demonstrated comparable levels of sensitivity and specificity in detecting MERS-CoV genetic variants as the EMC strain, which was used for primer construction. When using LAMP, mismatches in primer sequences seem to be tolerated, but mismatches can occur in the primer's 3′ end and the BIP primer should be avoided ([@bib0110]; [@bib0155]). In previous report, a mismatch in the BIP primer of the MERS-CoV N set slightly affected reactivity for the Riyadh-3 clade of MERS-CoV ([@bib0125]). However, this decrease in sensitivity was not seen in QProbe RT-LAMP. This difference might be due to the difference in detection mechanism.

It seems that a significant amount of the newly registered MERS-CoV sequences on GenBank are of dromedary origin. The QProbe RT-LAMP assays were also able to detect target sequences (synthesized RNA) derived from dromedary MERS-CoV. These data suggest that QProbe RT-LAMP assays can be used as an easy, rapid and reliable surveillance technique for MERS-CoV in the field-based studies for both humans and dromedaries.

5. Conclusions {#sec0070}
==============

In this study, QProbe RT-LAMP assays were developed for the detection of MERS-CoV. Quenching of fluorescence from labeled probe-specific reactions is measured as positive signals. These assays are capable of detecting MERS-CoV RNA at a level similar to that of standard real-time RT-PCR assays and the previously reported RT-LAMP, with no cross-reactivity observed with other respiratory viruses. QProbe RT-LAMP assays were demonstrated to be rapid, simple, and convenient as they employed a dry form of reagents and a portable fluorometer. QProbe RT-LAMP assays thus offer a reliable alternative for the diagnosis of MERS-CoV in humans and dromedaries. Altogether, these results indicate that the QProbe RT-LAMP assay can be used as a powerful tool for the diagnosis and surveillance of MERS-CoV infection in the field.
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[^1]: Capital letters indicate the sense strand; lowercase letters indicate the antisense strand.

[^2]: QP: Quenching probe

[^3]: QP: Quenching probe.

[^4]: PFU: plaque forming unit.

[^5]: FFU: focus forming unit.

[^6]: TCID50: median tissue culture infectious dose.

[^7]: Cq: quantification cycle value.

[^8]: Cq: quantification cycle value.

[^9]: Camel MERS-CoV sequences are indicated in bold.

[^10]: Based on EMC isolate (JX869059.2).

[^11]: Camel MERS-CoV sequences are indicated in bold.

[^12]: Based on EMC isolate (JX869059.2).
